| Literature DB >> 29875794 |
Lucas F daSilva1,2, Felipe C Beckedorff1,2, Ana C Ayupe1, Murilo S Amaral1,2, Vinícius Mesel2, Alexandre Videira1,2, Eduardo M Reis1, João C Setubal1,3, Sergio Verjovski-Almeida1,2.
Abstract
Cell signaling events triggered by androgen hormone in prostate cells is dependent on activation of the androgen receptor (AR) transcription factor. Androgen hormone binding to AR promotes its displacement from the cytoplasm to the nucleus and AR binding to DNA motifs, thus inducing activatory and inhibitory transcriptional programs through a complex regulatory mechanism not yet fully understood. In this work, we performed RNA-seq deep-sequencing of LNCaP prostate cancer cells and found over 7000 expressed long intergenic non-coding RNAs (lincRNAs), of which ∼4000 are novel lincRNAs, and 258 lincRNAs have their expression activated by androgen. Immunoprecipitation of AR, followed by large-scale sequencing of co-immunoprecipitated RNAs (RIP-Seq) has identified in the LNCaP cell line a total of 619 lincRNAs that were significantly enriched (FDR < 10%, DESeq2) in the anti-Androgen Receptor (antiAR) fraction in relation to the control fraction (non-specific IgG), and we named them Androgen-Receptor-Associated lincRNAs (ARA-lincRNAs). A genome-wide analysis showed that protein-coding gene neighbors to ARA-lincRNAs had a significantly higher androgen-induced change in expression than protein-coding genes neighboring lincRNAs not associated to AR. To find relevant epigenetic signatures enriched at the ARA-lincRNAs' transcription start sites (TSSs) we used a machine learning approach and identified that the ARA-lincRNA genomic loci in LNCaP cells are significantly enriched with epigenetic marks that are characteristic of in cis enhancer RNA regulators, and that the H3K27ac mark of active enhancers is conspicuously enriched at the TSS of ARA-lincRNAs adjacent to androgen-activated protein-coding genes. In addition, LNCaP topologically associating domains (TADs) that comprise chromatin regions with ARA-lincRNAs exhibit transcription factor contents, epigenetic marks and gene transcriptional activities that are significantly different from TADs not containing ARA-lincRNAs. This work highlights the possible involvement of hundreds of lincRNAs working in synergy with the AR on the genome-wide androgen-induced gene regulatory program in prostate cells.Entities:
Keywords: LNCaP prostate cancer cell line; androgen receptor; androgen receptor associated lincRNAs; epigenetic marks; genome-wide profiling; long intergenic non-coding RNAs; machine learning; random forest algorithm
Year: 2018 PMID: 29875794 PMCID: PMC5985396 DOI: 10.3389/fgene.2018.00132
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Number of novel and previously known lincRNAs expressed in LNCaP cells.
| LincRNAs expressed in LNCaP | Not responsive | Androgen responsive | |||
|---|---|---|---|---|---|
| Up-regulated | Down-regulated | Total | |||
| In the reference | 3043 | 2674 | 268 | 101 | 369 |
| Novel | 3979 | 3455 | 432 | 92 | 524 |
| Total | 7022 | 6129 | 700 | 193 | 893 |
LincRNAs differentially expressed in prostate patient tumor samples compared with adjacent non-tumor tissues.
| LincRNAs expressed in LNCaP cells anddetected in patient samplesa | No significant differential expressionb | Differentially expressed in patient tumor samplesb | |||
|---|---|---|---|---|---|
| Up-regulated | Down-regulated | Total | |||
| In the reference | 915 | 630 | 280 | 5 | 285 |
| Novel | 366 | 227 | 138 | 1 | 139 |
| Total | 1281 | 857 | 418 | 6 | 424 |
Androgen-responsive lincRNAs expressed in prostate patient samples and identification of the ones differentially expressed in tumor.
| LincRNAs responsive to androgen in LNCaP cells, and detected in patient samplesa | No significant differential expressionb | Differentially expressed in patient tumor samplesb | |||
|---|---|---|---|---|---|
| Up-regulated | Down-regulated | Total | |||
| In the reference up-regulated by androgen | 73 | 43 | 29 | 1 | 30 |
| In the reference down-regulated by androgen | 44 | 30 | 13 | 1 | 14 |
| Novel up-regulated by androgen | 26 | 13 | 13 | 0 | 13 |
| Novel down-regulated by androgen | 14 | 4 | 10 | 0 | 10 |
| Total | 157 | 90 | 65 | 2 | 67 |